Pipeline

Program Therapeutic Area/Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Post Market Commercial Rights
Internal Programs
Etrasimod
Optimized Activity S1P Receptor Modulator
ELEVATE UC 52

73%

ELEVATE UC 12

73%

CULTIVATE – Crohn’s Disease (CD)

73%

ADVISE – Atopic Dermatitis (AD)

55%

Arena: Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories
Olorinab
Highly Selective Full Agonist CB2
CAPTIVATE – IBS Pain

55%

IBD Pain

45%

Arena: Worldwide
APD418 Calcium-Independent Myotrope
Decompensated heart failure (DHF)

17%

Arena: Worldwide
Partnered / Licensed Programs
Ralinepag (Potent IP Receptor Agonist)
Pulmonary Arterial Hypertension (PAH)

75%

United Therapeutics
BELVIQ and BELVIQ XR
Weight Loss Approved: CVOT Completed

98%

Eisai: Worldwide
Undisclosed Orphan GPCR
CNS

15%

Boehringer Ingelheim
OP-352
Genitourinary Disorders

30%

Outpost Medicine
Program Therapeutic Area/Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Post Market Commercial Rights

Program Indication Phase
Internal Programs
Etrasimod
Optimized Activity S1P Receptor Modulator
ELEVATE UC 52 Ph3 Ongoing
ELEVATE UC 12 Ph3 Planning
Crohn’s Disease (CD) Ph2b/3 Planning
Atopic Dermatitis (AD) Ph2 Ongoing
Olorinab
Highly Selective Full Agonist CB2
Pain Associated with IBS Ph2b Ongoing
Pain Associated with IBD Ph2b Planning
APD418
Calcium-Independent Myotrope
Decompensated heart failure (DHF) IND 2019
Partnered / Licensed Programs
Ralinepag (Potent IP Receptor Agonist)
Pulmonary Arterial Hypertension (PAH) Ph3
BELVIQ and BELVIQ XR
Weight Loss Approved: CVOT Completed Post Market
Undisclosed Orphan GPCR
CNS PC
OP-352
Genitourinary Disorders Ph1

Expanded Access Policy

Last updated as of 11/7/19